When it comes to cystic fibrosis Vertex is the undisputed heavyweight, but this has not stopped other groups from taking it on. Abbvie is the latest challenger, and data due this quarter could give clues about whether the group was wise to go all in on projects originated by Galapagos.
Abbvie has two phase 2 trials under way, one of a doublet and one of a triplet. The big pharma reckons it can do better than Vertex’s latest drug, the triplet Trikafta, in terms of efficacy – but an edge on tolerability could also be enough to justify moving forward, Abbvie execs hinted at the JP Morgan meeting this week.
JPMorgan Multi-Asset Growth & Income plc (LON:MATE) combines sustainable income and capital growth from globally diversified investments. The Investment Trust’s multi-asset investing approach aims to achieve a long-term total return of 6% per annum and an initial annual dividend of 4% paid quarterly. This provides an attractive income investing and capital growth opportunity while seeking to maintain lower levels of portfolio volatility than a traditional equity portfolio.